Matthew W. Davis's most recent trade in Aquestive Therapeutics Inc was a trade of 50,000 Common Stock done . Disclosure was reported to the exchange on Nov. 10, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Aquestive Therapeutics Inc | Matthew W. Davis | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Nov 2025 | 50,000 | 50,000 (0%) | 0% | 0 | Common Stock | |
| Aquestive Therapeutics Inc | Matthew W. Davis | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Nov 2025 | 50,000 | 50,000 | - | - | Non-Qualified Stock Option (right to buy) |